title: Advancing Precision Nuclear Medicine and Molecular Imaging for Lymphoma.
abstract: PET with fluorodeoxyglucose F 18 (18F FDG-PET) is a meaningful biomarker for the detection, targeted biopsy, and treatment of lymphoma. This article reviews the evolution of18F FDG-PET as a putative biomarker for lymphoma and addresses the current capabilities, challenges, and opportunities to enable precision medicine practices for lymphoma. Precision nuclear medicine is driven by new imaging technologies and methodologies to more accurately detect malignant disease. Although quantitative assessment of response is limited, such technologies will enable a more precise metabolic mapping with much higher definition image detail and thus may make it a robust and valid quantitative response assessment methodology.
authors.affiliation: Wright Center of Innovation in Biomedical Imaging, Division of Imaging Science, Department of Radiology, The Ohio State University Wexner Medical Center, 395 West 12th Avenue, Room 430, Columbus, OH 43210, USA.
authors.forename: Chadwick L
authors.initials: CL
authors.lastname: Wright
authors.affiliation: Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Starling Loving Hall 406C, 320 West 10th Avenue, Columbus, OH 43210, USA.
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Maly
authors.affiliation: Wright Center of Innovation in Biomedical Imaging, Division of Imaging Science, Department of Radiology, The Ohio State University Wexner Medical Center, 395 West 12th Avenue, Room 430, Columbus, OH 43210, USA.
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Wright Center of Innovation in Biomedical Imaging, Division of Imaging Science, Department of Radiology, The Ohio State University Wexner Medical Center, 395 West 12th Avenue, Room 430, Columbus, OH 43210, USA. Electronic address: knopp.16@osu.edu.
authors.forename: Michael V
authors.initials: MV
authors.lastname: Knopp
mesh_terms: D014408:Biomarkers, Tumor; D001706:Biopsy; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008223:Lymphoma / Q000000981:diagnostic imaging* / Q000628:therapy*; D057054:Molecular Imaging; D058990:Molecular Targeted Therapy; D049268:Positron-Emission Tomography / Q000379:methods*; D057285:Precision Medicine; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals
chemical_list: D014408:Biomarkers, Tumor; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: Biomarker; Fluorodeoxyglucose; Lymphoma; Molecular imaging; Position emission tomography; Precision medicine